by TractManager | Jul 9, 2019 | Emerging Technology Report
Luxturna (voretigene neparvovec-rzyl) is an adenovirus-associated viral vector serotype 2 gene therapy containing the human RPE65 gene for treatment of patients with vision loss due to RPE65-mediated inherited retinal disease. Gene therapy utilizes a viral vector to...
by TractManager | Jul 8, 2019 | Emerging Technology Report
Libtayo (cemiplimab) is an intravenous programmed death receptor-1 (PD-1) blocking antibody indicated for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who are not candidates for curative surgery or...
by TractManager | Jul 8, 2019 | Emerging Technology Report
Libtayo (cemiplimab) is an intravenous programmed death receptor-1 (PD-1) blocking antibody indicated for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who are not candidates for curative surgery or...
by TractManager | Jul 2, 2019 | Emerging Technology Report
Dextenza is a sustained-release dexamethasone hydrogel intracanalicular insert for the treatment of ocular pain and inflammation after ophthalmic surgery. The insert is a rod-shaped biodegradable hydrogel intracanalicular device that delivers 0.4 mg dexamethasone in...
by TractManager | Jul 2, 2019 | Health Technology Assessment
Health Problem: Glaucoma is a disease of the optic nerve characterized by loss of retinal ganglion cells; remodeling of the lamina cribrosa; structural changes to the nerve; elevated intraocular pressure (IOP); and progressive, irreversible loss of vision leading to...
Recent Comments